LONDON, Nov. 13, 2019 /PRNewswire/ -- Abingworth, the
international investment group dedicated to life sciences, today
announced the appointment of Neil
Cooper as Chief Financial Officer, based in the London office. He succeeds James Abell who is retiring after 21 years with
the firm.
Neil has 19 years' professional experience in venture capital,
private equity and financial services. He joins Abingworth from
Kennet Partners Ltd, an international growth equity company, at
which he was Finance Director. He has previously held senior
finance roles at Robert W Baird, Baird Capital Partners Europe and
at Advent Venture Partners. Neil is a qualified Chartered
Accountant and holds a degree in Biochemistry from the University of Warwick.
Neil's role at Abingworth will be to manage the finances and
administration of the business across its locations in the UK and
US and to support fundraising and investment activities.
Tim Haines, Chairman &
Managing Partner, said: "I am delighted to welcome Neil to the
Abingworth team. He brings excellent financial management
experience as well as a high level of operational knowledge of
working in the venture capital and private equity space. We are
confident that, with these skills and experience, Neil will ensure
the continued smooth running of all financial aspects of the
business."
"I would also like to take this opportunity on behalf of the
Abingworth team to thank James Abell
for his dedicated service over the past two decades. He has been
integral to the success of the company over that period,
significantly impacting all aspects of the financial and
operational functioning of the firm and in the process setting
incredibly high standards that will continue to serve as strong
foundations for the future. We wish him a very well deserved and
enjoyable retirement."
Neil Cooper added: "I am excited
to be joining a company with such a strong heritage and successful
track record as a transatlantic investor in the life sciences
sector. Working in this dynamic environment and with the excellent
Abingworth team, I am well equipped to continue and progress the
outstanding work that James has done. I look forward to
getting started."
About Abingworth
Abingworth is a leading transatlantic life sciences investment
firm. We help transform cutting-edge science into novel medicines
by providing capital and expertise to top calibre management teams
and building world-class companies. Since 1973, Abingworth has
invested in approximately 160 life science companies, leading to
more than 40 M&A/exits and over
65 IPOs. Our therapeutic focused investments fall into 3
categories: seed and early-stage, development stage, and clinical
co-development. Abingworth supports its portfolio companies
with a team of experienced professionals at offices in London, Menlo
Park (California) and
Boston.
Contacts
Tim Haines
Chairman & Managing Partner
Tel: +44-(0)20-7534-1500
www.abingworth.com
For media enquiries:
Mark Swallow or David Dible, Citigate Dewe Rogerson
Tel: +44(0)20-7638-9571
Email: abingworth@citigatedewerogerson.com